Developing safe and effective generic ophthalmic drug products requires a clear understanding of how formulation characteristics influence drug delivery to the eye. In this peer-reviewed study published in the International Journal of Pharmaceutics, researchers from Biostudy Solutions, the U.S. Food and Drug Administration (FDA), and leading academic institutions investigated the pharmacokinetics of brinzolamide ophthalmic suspensions to better understand the relationship between formulation properties, ocular drug absorption, and study design for bioequivalence research.
The study evaluated the commercially available Azopt® ophthalmic suspension alongside five experimental formulations with varying particle size distributions and viscosities. Using rabbit models, researchers measured drug concentrations across multiple ocular tissues and found that differences in these formulation attributes did not produce statistically significant changes in peak drug concentrations. The team also performed an extensive variability analysis, demonstrating that a paired-eye dosing design dramatically reduces the number of animals required for pharmacokinetic studies while maintaining strong statistical power compared to traditional parallel-group studies.
These findings provide important guidance for ophthalmic drug development, generic drug research, and regulatory strategy by improving study efficiency while supporting the development of meaningful in vitro–in vivo correlations (IVIVC). The research highlights Biostudy Solutions' expertise in biostatistics, pharmacokinetic analysis, study design optimization, variance analysis, bioequivalence research, and regulatory science, helping pharmaceutical companies design more efficient studies that meet FDA expectations while reducing development time and resource requirements.
